Updated November 2021 DGL bulletin data—In November, for the whole market, Keytruda still remains in the first place in the ranking. Interestingly, NHF spending on its reimbursement increased by 81.0% compared to 2020, with cumulative reimbursement value from January to November 2021 of 253 million, while the total amount of reimbursement for 2020 was 172 million. The increase may be… Czytaj dalej #TOP10 reimbursement value in Poland – November 2021
Updated October 2021 DGL bulletin dataIn October, for the whole market, Keytrude remains in the first place in the ranking, but NHF spending on its reimbursement increased by 76.5% compared to 2020. Spinraza has dropped two more places (from 4th to 6th) while Xtandi moved to 7th place from 8th, with a 50,8% increase in the amount of… Czytaj dalej #TOP10 reimbursement value in Poland
The list of medicines of high clinical value, published on August 26, 2021, includes 35 medical technologies – including 30 medicinal products registered by #EMA in 2017-2020. In the period from 01/01/2017 to 31/12/2020, 951 drug technologies (for 321 medicinal products) were registered by EMA. The final list was selected by #AOTMiT from 374 medical technologies (39%) left after… Czytaj dalej MF – The list of medicines of high clinical value
Updated April #DGL bulletin data NHF spending on medical products from drug programmes from January till April 2021 amounted to PLN 1.42 billion and are 18% higher than reimbursement amount in the same period of the previous year. More in our updated IDA TOP10 report.
TOP 10 reimbursement value for brands NHF spending on medical products, foodstuffs and medical devices reimbursement from January till February 2021 amounted to PLN 2.09 billion, including PLN 1.37 billion expenditures on products from outpatients list, PLN 0.65 billion on medical products from drug programmes and PLN 0.07 billion on products from chemotherapy. NHF spending… Czytaj dalej TOP 10 reimbursement value for brands